

## WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

**[HA467 trade name]\***

Ritonavir 100 mg tablets

[HA467 trade name], manufactured at Mylan Laboratories Limited, Maharashtra and Madhya Pradesh, India, was included in the WHO list of prequalified medicinal products for the treatment of HIV/AIDS on 14 December 2010.

[HA467 trade name] is currently indicated as a pharmacokinetic enhancer for protease inhibitors when these are used in combination therapy with other antiretroviral agents for the treatment of HIV-1 infected patients. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [HA467 trade name] is ritonavir. The efficacy and safety of ritonavir are well established based on extensive clinical experience in the treatment of HIV/AIDS.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of ritonavir, the team of assessors advised that [HA467 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [HA467 trade name] in the list of prequalified medicinal products.

### Summary of prequalification status for [HA467 trade name]:

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

Initial acceptance	Date	Outcome
Status on PQ list	Dec 2010	Listed
Pharmaceutical quality	Nov 2010	MR
Bioequivalence	Dec 2010	MR
Safety, efficacy	Dec 2010	MR
<b>GMP (re-)inspection</b>		
API	June 2008	MR
FPP	Aug 2009	MR
<b>GCP/GLP (re-)inspection</b>	Apr 2009	MR
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification		

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

\*\* Previously known as Matrix Laboratories Limited.

<b>Requalification</b>	31 October 2019
------------------------	-----------------